SLS ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 2 | Amyotrophic lateral sclerosis | 2 |
2. Amyotrophic lateral sclerosis
Clinical trials : 624 / Drugs : 611 - (DrugBank : 160) / Drug target genes : 172 - Drug target pathways : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05136885 (ClinicalTrials.gov) | February 2022 | 14/11/2021 | HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose | HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose | Amyotrophic Lateral Sclerosis | Drug: SLS-005;Drug: Matching Placebo | Merit E. Cudkowicz, MD | Seelos Therapeutics, Inc. | Not yet recruiting | 18 Years | N/A | All | 160 | Phase 2/Phase 3 | NULL |
| 2 | NCT04297683 (ClinicalTrials.gov) | July 14, 2020 | 3/3/2020 | HEALEY ALS Platform Trial - Master Protocol | HEALEY ALS Platform Trial | Amyotrophic Lateral Sclerosis | Drug: Zilucoplan;Drug: Verdiperstat;Drug: CNM-Au8;Drug: Pridopidine;Drug: SLS-005 Trehalose | Merit E. Cudkowicz, MD | Massachusetts General Hospital | Recruiting | 18 Years | N/A | All | 800 | Phase 2/Phase 3 | United States |